<DOC>
	<DOC>NCT02016729</DOC>
	<brief_summary>Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.</brief_summary>
	<brief_title>A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Men or women &gt; 18 years old Pathologicallydocumented, definitivelydiagnosed AML that is relapsed or refractory to standard treatment, for which no standard therapy is available or the subject refuses standard therapy Ability to take oral medications and willing to record daily adherance to investigational product Adequate hematological, renal, hepatic, and coagulation laboratory assessments Active infection requiring intravenous (IV) antibiotics Prior participation in an investigational study (procedure or device) within 21 days of study day 1 Major surgery within 28 days of study day 1 Antitumor therapy within 14 days of study day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AML</keyword>
</DOC>